Sanofi may try to make a buy offer but they won't push it too hard. REGN is perfectly comfortable with their partnership arrangement with SNF and look at how well that company stock is doing. And MNKD is going down the same path. A little patience and this stock is GTTMA.
Unless something devastating happens I think the wood floors are in. I bought in at $2.54. Some patience and this will be back into double digits. A. Denner will be evaluating deals as well. This baby is so cheap and they also have the ED scripts. The big question is on the generic side which will either lead to a partnership or buyout if the tide goes against.
Well I invested my nickel. I anticipate some news coming along soon. If a buyout is in the making then I say it's worth at least $11.
Saw a Belviq commercial earlier this week so ARNA is hitting the trail. Agreed that VVUS needs to put the cash to work.
Buying up all that I can. This reminds me of NBIX when it got dumped and then bounced back to $40. Patience towards a nice big return. Thanks for dropping the price down so low
Buckle up the seat belts. Analyst upgrades are on the way....
Exactly! When you can let go of the resentments and regrets then you can move on in peace and make money while the sick get better health treatment. I look for these types of unhidden gems. Bought big into VVUS because it's so oversold like AEZS (trading far less than cash on hand with two drugs on the market). Patience is key in a turnaround.
I wouldn't say that it's a serious negative because Denner knows how to pair management teams with biotech. He's skilled at it. If a company needs to be shaken up and have their bloated salaries tied into performance then I'm all for it. I don't agree with the stealing of IP but if a company needs to get bought out to preserve shareholder value (being that I'm an owner) then I'm for it. It is a balancing act to curb abuse on both sides. After all, Denner is looking to make a profit for his hedge funds just like you are looking to make a profit on your investment. Something has to happen with AVEO and right now there is no clear direction.
I thought that I might get it around $2.75 and I should've traded it this morning because the price pulled back a little bit then kept charging forward (stinkin thinkin on my part but you never know). Regardless, the earnings are expected to beat expectations. I anticipate this stock going to $7 in the next few months because the price is so depressed. It's trading for less than cash reserves which is a golden opportunity. $2.40 was the bottom and it's nice to get in under $3. Should see the $3s tomorrow.
It's probably best if he is retained as a consultant and let a new CEO run the ship. Too many of these founders treat the company like it's still their baby even though the investors now own the company. You have to do what is right for the shareholders (company owners). HB must get out of the way of the moving freight train.
It's obvious that HB has a couple of weeks to negotiate his exit package. And to work on his retirement plan. If he stays, the stock will drop big time. So, Pfizer will start the bid in the $20s and it will go up from there. What reason was there that Ariad is trading so low when companies like NBIX have price rocketed over the past year? Well, the reason is HB.
It'll be a fun quarter. The new CEO will be a puppet on strings while Denner and board reel in the offers. You can bet the big pharmas are positioning as I write this. Denner is not going to take less than $40/share as he needs to make up for the past couple of years of loss. Icahn is working behind the curtain....
like he is doing with Ariad and force some changes. Klarman leaving is old news and some new institutions have bought in. The company should lay out a solid 3 year execution plan or look to be acquired for $10/share. There's no reason why this stock is in such doldrums.
The board will probably offer Harvey the chance to save face and a decent parachute out. They will remove the poison pill and open it up for bidding. Given the short term horizon, I don't think they should accept anything less than $35/share. The momentum will build up through March.